Water-soluble fullerene derivatives: the inhibition effect on polyol pathway enzymes and antidiabetic potential on high-fat diet/low-dose streptozotocin-induced diabetes in rats
Source abstract
Abstract
Water-soluble pentaamino acid fullerene (C60) derivatives (PFD) are promising nanomaterials with a wide range of biomedical applications. The present study has shown that PFD-7 competitively inhibits aldose reductase and sorbitol dehydrogenase, enzymes of the polyol pathway of glucose metabolism, which are known to be associated with diabetic complications. Treatment with PFD-7 was associated with a decrease in blood glucose level and improvement pancreas and liver morphology in rats with type 2 diabetes mellitus (induced by a high fat diet and streptozotocin). The data obtained indicating the ability of pentaamino acid fullerene (C60) derivatives to exhibit a pronounced antidiabetic effect. Thus, PFD-7 may be considered to contribute significantly to treatment of type 2 diabetes mellitus and diabetic complications.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Aldose Reductase and Taurine · Fullerene Chemistry and Applications · Pancreatic function and diabetes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. International Diabetes Federation (2019) IDF Diabetes Atlas, 9th edn. International Diabetes Federation, Brussels, Belgium
2. American Diabetes Association (2019) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019. Diabetes Care 42:S13–S28. https://doi.org/10.2337/dc19-S00210.2337/dc19-S002 ↗
3. World Health Organization (2019) Classification of diabetes mellitus. World Health Organization, Geneva, Switzerland
4. Reddy TN, Ravinder M, Bagul P et al (2014) Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs). Eur J Med Chem 71:53–66. https://doi.org/10.1016/j.ejmech.2013.10.04310.1016/j.ejmech.2013.10.043 ↗
5. Obrosova IG (2005) Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 7:1543–1552. https://doi.org/10.1089/ars.2005.7.154310.1089/ars.2005.7.1543 ↗
6. Hwang SH, Wang Z, Guillen Quispe YN et al (2018) Evaluation of aldose reductase, protein glycation, and antioxidant inhibitory activities of bioactive flavonoids in matricaria recutita L. and their structure-activity relationship. J Diabetes Res 2018:1–11. https://doi.org/10.1155/2018/327616210.1155/2018/3276162 ↗
7. Yan L (2018) Redox imbalance stress in diabetes mellitus: role of the polyol pathway. Anim Model Exp Med 1:7–13. https://doi.org/10.1002/ame2.1200110.1002/ame2.12001 ↗
8. Kumar S, Kumar A, Mustufa Khan M (2019) Estimation of aldose reductase activity and malondialdehyde levels in patients with type 2 diabetes mellitus. Biomed Pharmacol J 12:1001–1007. https://doi.org/10.13005/bpj/172810.13005/bpj/1728 ↗
9. Lee H, Kim J, Whang W (2017) Chemical constituents of smilax china L. stems and their inhibitory activities against glycation aldose reductase, α-glucosidase, and lipase. Molecules 22:451. https://doi.org/10.3390/molecules2203045110.3390/molecules22030451 ↗
10. Takagi Y, Kashiwagi A, Tanaka Y et al (1995) Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabetes Complications 9:87–91. https://doi.org/10.1016/1056-8727(94)00022-G10.1016/1056-8727(94)00022-G ↗
11. Yan LJ (2014) Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res 2014:1–11. https://doi.org/10.1155/2014/13791910.1155/2014/137919 ↗
12. Schemmel KE, Padiyara RS, D’Souza JJ (2010) Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 24:354–360. https://doi.org/10.1016/j.jdiacomp.2009.07.00510.1016/j.jdiacomp.2009.07.005 ↗
13. Kumar MP, Sankeshi V, Naik RR et al (2015) The inhibitory effect of Isoflavones isolated from Caesalpinia pulcherrima on aldose reductase in STZ induced diabetic rats. Chem Biol Interact 237:18–24. https://doi.org/10.1016/j.cbi.2015.05.01010.1016/j.cbi.2015.05.010 ↗
14. Petrovic D, Seke M, Srdjenovic B, Djordjevic A (2015) Applications of anti/prooxidant fullerenes in nanomedicine along with fullerenes influence on the immune system. J Nanomater 16:1–11. https://doi.org/10.1155/2015/56563810.1155/2015/565638 ↗
15. Cataldo F, Da Ros T (2008) Medicinal chemistry and pharmacoloical potential of fullerenes and carbon nanotubes. Springer Science & Business Media10.1007/978-1-4020-6845-4 ↗
16. Wang M, Maragani S, Huang L et al (2013) Synthesis of decacationic [60]fullerene decaiodides giving photoinduced production of superoxide radicals and effective PDT-mediation on antimicrobial photoinactivation. Eur J Med Chem 63:170–184. https://doi.org/10.1016/j.ejmech.2013.01.05210.1016/j.ejmech.2013.01.052 ↗
17. Ma H, Zhao J, Meng H et al (2020) Carnosine-modified fullerene as a highly enhanced ros scavenger for mitigating acute oxidative stress. ACS Appl Mater Interfaces 12:16104–16113. https://doi.org/10.1021/acsami.0c0166910.1021/acsami.0c01669 ↗
18. Markovic Z, Trajkovic V (2008) Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials 29:3561–3573. https://doi.org/10.1016/j.biomaterials.2008.05.00510.1016/j.biomaterials.2008.05.005 ↗
19. Ikeda A, Iizuka T, Maekubo N et al (2013) Cyclodextrin complexed [60]fullerene derivatives with high levels of photodynamic activity by long wavelength excitation. ACS Med Chem Lett 4:752–756. https://doi.org/10.1021/ml400153510.1021/ml4001535 ↗
20. Hsieh FY, Zhilenkov AV, Voronov II et al (2017) Water-soluble fullerene derivatives as brain medicine: surface chemistry determines if they are neuroprotective and antitumor. ACS Appl Mater Interfaces 9:11482–11492. https://doi.org/10.1021/acsami.7b0107710.1021/acsami.7b01077 ↗
21. Vorobyov V, Kaptsov V, Gordon R et al (2015) Neuroprotective effects of hydrated fullerene C60: cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer’s disease. J Alzheimer’s Dis 45:217–233. https://doi.org/10.3233/JAD-14246910.3233/JAD-142469 ↗
22. Kotelnikova RA, Smolina AV, Zhilenkov AV et al (2018) Interaction of water-soluble pentaamino acid fullerene derivatives with membranes of phosphatidylcholine liposomes. Russ Chem Bull 67:366–370. https://doi.org/10.1007/s11172-018-2082-y10.1007/s11172-018-2082-y ↗
23. Kotel’nikova RA, Faingol’d II, Poletaeva DA et al (2011) Antioxidant properties of water-soluble amino acid derivatives of fullerenes and their role in the inhibition of herpes virus infection. Russ Chem Bull 60:1172–1176. https://doi.org/10.1007/s11172-011-0184-x10.1007/s11172-011-0184-x ↗
24. Iwasaki Y, Ikeda H, Araki Y et al (2006) Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatol 43:54–63. https://doi.org/10.1002/hep.2098410.1002/hep.20984 ↗
25. Troshina OA, Troshin PA, Peregudov AS et al (2007) Chlorofullerene C60Cl6: a precursor for straightforward preparation of highly water-soluble polycarboxylic fullerene derivatives active against HIV. Org Biomol Chem 5:2783–2791. https://doi.org/10.1039/b705331b10.1039/b705331b ↗
26. Medrek M, Pluciński F, Mazurek AP (2013) Endohedral complexes of fullerene C60 with small convalent molecules (H2O, NH3, H2, 2H2, 3H2, 4H2, O2, O3) in the context of potential drug transporter system. Acta Pol Pharm 70:659–665
27. Hosseini A, Abdollahi M, Hassanzadeh G et al (2011) Protective effect of magnesium-25 carrying porphyrin-fullerene nanoparticles on degeneration of dorsal root ganglion neurons and motor function in experimental diabetic neuropathy. Basic Clin Pharmacol Toxicol 109:381–386. https://doi.org/10.1111/j.1742-7843.2011.00741.x10.1111/j.1742-7843.2011.00741.x ↗
28. Nedzvetskii VS, Pryshchepa IV, Tykhomyrov AA, Baydas G (2016) Inhibition of reactive gliosis in the retina of rats with streptozotocin-induced diabetes under the action of hydrated C60 fullerene. Neurophysiol 48:130–140. https://doi.org/10.1007/s11062-016-9579-510.1007/s11062-016-9579-5 ↗
29. Nedzvetsky V, Andrievsky G (2012) Differences in antioxidant/protective efficacy of hydrated C60 fullerene nanostructures in liver and brain of rats with streptozotocin-induced diabetes. J Diabetes Metab 3:1–9. https://doi.org/10.4172/2155-6156.100021510.4172/2155-6156.1000215 ↗
30. Gispen WH, Biessels G-J (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23:542–549. https://doi.org/10.1016/S0166-2236(00)01656-810.1016/S0166-2236(00)01656-8 ↗
31. Karaağaç N, Salman F, Doğru-Abbasoğlu S, Uysal M (2011) Changes in prooxidant–antioxidant balance in tissues of rats following long-term hyperglycemic status. Endocr Res 36:124–133. https://doi.org/10.3109/07435800.2011.56623710.3109/07435800.2011.566237 ↗
32. Wong C-W, Zhilenkov AV, Kraevaya OA et al (2019) Toward understanding the antitumor effects of water-soluble fullerene derivatives on lung cancer cells: apoptosis or autophagy pathways? J Med Chem 62:7111–7125. https://doi.org/10.1021/acs.jmedchem.9b0065210.1021/acs.jmedchem.9b00652 ↗
33. Kornev AB, Khakina EA, Troyanov SI et al (2012) Facile preparation of amine and amino acid adducts of [60]fullerene using chlorofullerene C60Cl6 as a precursor. Chem Commun (camb) 48:5461–5463. https://doi.org/10.1039/c2cc00071g10.1039/c2cc00071g ↗
34. Troshin PA, Kornev AB, Khakina EA, Razumov VF (2010) Aminofullerenes and synthesis method thereof. RF Patent No 2 460 688 C2. 27
35. Motaal A, El-Askary H, Crockett S et al (2015) Aldose reductase inhibition of a saponin-rich fraction and new furostanol saponin derivatives from Balanites aegyptiaca. Phytomedicine 22:829–836. https://doi.org/10.1016/j.phymed.2015.05.05910.1016/j.phymed.2015.05.059 ↗
36. Sevela M, Tovarek J (1961) Fotometricka metoda stanoveni dehydrogenase sorbitol. Vintrni Lek 1392–1397
37. Furman BL (2015) Streptozotocin-induced diabetic models in mice and rats. In: Current Protocols in Pharmacology. John Wiley & Sons, Inc., Hoboken, NJ, USA, pp 5.47.1–5.47.2010.1002/0471141755.ph0547s70 ↗
38. Reed M, Meszaros K, Entes L et al (2000) A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49:1390–1394. https://doi.org/10.1053/meta.2000.1772110.1053/meta.2000.17721 ↗
39. Srinivasan K, Viswanad B, Asrat L et al (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52:313–320. https://doi.org/10.1016/j.phrs.2005.05.00410.1016/j.phrs.2005.05.004 ↗
40. Yorek MA (2016) Alternatives to the streptozotocin-diabetic rodent. In: Nigel A. Calcutt PF (ed) International review of neurobiology. Academic Press, pp 89–1110.1016/bs.irn.2016.03.002 ↗
41. Yu T, Sungelo M, Goldberg I et al (2017) Streptozotocin-treated high fat fed mice: a new type 2 diabetes model used to study canagliflozin-induced alterations in lipids and lipoproteins. Horm Metab Res 49:400–406. https://doi.org/10.1055/s-0042-11093410.1055/s-0042-110934 ↗
42. Barrière DA, Noll C, Roussy G et al (2018) Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. Sci Rep 8:424. https://doi.org/10.1038/s41598-017-18896-510.1038/s41598-017-18896-5 ↗
43. Broeke J, Pérez JMM, Pascau J (2015) Image processing with Image J. Packt Publishing Ltd, Birmingham, UK
44. Partha R, Lackey M, Hirsch A et al (2007) Self assembly of amphiphilic C60 fullerene derivatives into nanoscale supramolecular structures. J Nanobiotechnol 5:6. https://doi.org/10.1186/1477-3155-5-610.1186/1477-3155-5-6 ↗
45. Lorenzi M (2007) The Polyol Pathway as a Mechanism for Diabetic Retinopathy: Attractive, Elusive, and Resilient. Exp Diabetes Res 2007:1–10. https://doi.org/10.1155/2007/6103810.1155/2007/61038 ↗
46. Shek PN, Howe SA (1982) A novel method for the rapid bleeding of rats from the tail vein. J Immunol Methods 53:255–260. https://doi.org/10.1016/0022-1759(82)90148-X10.1016/0022-1759(82)90148-X ↗
47. Maekawa K, Tanimoto T, Okada S et al (2001) Expression of aldose reductase and sorbitol dehydrogenase genes in Schwann cells isolated from rat: effects of high glucose and osmotic stress. Mol Brain Res 87:251–256. https://doi.org/10.1016/S0169-328X(01)00009-210.1016/S0169-328X(01)00009-2 ↗
48. Hwang YC, Bakr S, Ellery CA et al (2003) Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J 17:2331–2333. https://doi.org/10.1096/fj.03-0128fje10.1096/fj.03-0128fje ↗
49. Saito R, Suzuki S, Sasaki K (2016) Pterin-7-carboxamides as a new class of aldose reductase inhibitors. Bioorg Med Chem Lett 26:4870–4874. https://doi.org/10.1016/j.bmcl.2016.09.03310.1016/j.bmcl.2016.09.033 ↗
50. Sayes CM, Fortner JD, Guo W, Lyon D, Boyd AM, Ausman KD et al (2004) The differential cytotoxicity of water-soluble fullerenes. Nano Lett 4:1881–1887. https://doi.org/10.1021/nl048958610.1021/nl0489586 ↗